Neuralace

INTELLECTUAL PROPERTY

Neuralace Medical
Intellectual Property

VIRTUAL PATIENT MARKING

The following products are protected in the US and elsewhere. This page is intended to satisfy applicable virtual patent marking

requirements of various jurisdictions, including those of the America Invents Act and to provide notice under 35 U.S.C. Section 287(a).

The following list of products and patents may not be all inclusive. Additional patents and patent applications are issued and pending.

Product

Patent(s)
AXON Therapy System
US Pat 10,369,373; US Pat. 11,273,317; Patent Pending

TRADEMARKS

The following trademarks are owned by Neuralace Medical, Inc.

Axon (US TM Reg. No. 6761208)

Class

010 Medical device and instruments for the management of chronic nerve pain, namely, a non-invasive magnetic pulse stimulation system that make use of algorithms and signal processing technology for targeted peripheral nerve stimulation for treating patients with chronic nerve pain.

Neuralace Medical (US TM App. 97428198)

Class

010 Medical device and instruments for the management of chronic nerve pain, namely, a non-invasive magnetic pulse stimulation system that make use of algorithms and signal processing technology for targeted peripheral nerve stimulation for treating patients with chronic nerve pain.

Find Out More About Axon Therapy mPNS

Keith Warner

Chief Executive Officer

Proactive and engaging leader with expertise in advanced strategy development and implementation driving outstanding corporate growth. Over 25 years of senior level business acumen gained through key executive positions with leading large cap to venture stage startups within the life sciences and medical technology sectors. Experience in organization-building geared to achieve near and long term milestones both in domestic and international settings. Ability to deliver significant transformation and growth in financial performance, product development, investor fundraising, capital restructuring, P&L management, and strategic planning.